John F. Crowley - Jan 9, 2024 Form 4/A Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Signature
/s/ Christian Formica, Attorney-in-Fact
Stock symbol
FOLD
Transactions as of
Jan 9, 2024
Transactions value $
-$934,659
Form type
4/A
Date filed
3/15/2024, 07:14 PM
Date Of Original Report
Jan 11, 2024
Previous filing
Jan 5, 2024
Next filing
Jan 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Award $0 +57.6K +6.14% $0.00 995K Jan 9, 2024 Direct F1, F2
transaction FOLD Common Stock Tax liability -$503K -36.9K -3.7% $13.65 959K Jan 9, 2024 Direct F2
transaction FOLD Common Stock Sale -$431K -31.6K -3.3% $13.65 927K Jan 10, 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John F. Crowley is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
F2 On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
F3 This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

The sale transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2023.